Tuberculosis (TB) and particularly drug-resistant TB continue to represent major public health threats in the WHO European Region. This document details the Tuberculosis action ...tribute-to-highlight medbox">plan for the WHO European Region 2023–2030 as well as its monitoring and evaluation framework and outlines the vision and strategic actions for the TB response in the Region for this period. Developed through a Region-wide participatory consultation process, the TB action plan aims to support Member States to implement their national responses to the TB epidemic and provides strategies to enable the Region to reach the global End TB Strategy targets as well as aligning to the priorities of the European Programme of Work, 2020–2025 – “United Action for Better Health in Europe”.
more
The World Health Organization (WHO) Global Tuberculosis Report 2021 estimated that, in 2020, tuberculosis (TB) was the second most common infectious disease killer after coronavirus disease (COVID-19) and the 13th leading cause of death (1). Twenty-...five per cent (25%) of the world’s population has latent TB infection, which can develop into disease. In 2020, WHO estimated that 9.9 million people fell ill with TB, but only about 5.8 million (60%) were diagnosed, reported and treated, an 18% fall from 7.1 million in 2019. WHO also estimates that, between 2019 and 2020, global TB mortality increased from 1.2 to 1.5 million, a 5.6% increase
more
The World Health Organization (WHO) Global Tuberculosis Report 2021 estimated that, in 2020, tuberculosis (TB) was the second most common infectious disease killer after coronavirus disease (COVID-19) and the 13th leading cause of death (1). Twenty-...five per cent (25%) of the world’s population has latent TB infection, which can develop into disease. In 2020, WHO estimated that 9.9 million people fell ill with TB, but only about 5.8 million (60%) were diagnosed, reported and treated, an 18% fall from 7.1 million in 2019. WHO also estimates that, between 2019 and 2020, global TB mortality increased from 1.2 to 1.5 million, a 5.6% increase
more
Maldives has made significant strides in the area of infectious disease prevention and control. This is exemplified by elimination of malaria from Maldives in 2015 and successes in TB control. In addition, Maldives is a front runner in infectious di...sease prevention through successful water, sanitation, hygiene and vaccination campaigns and coverage. However, given the limited evidence that exists with respect to the occurrence of resistant organisms in the nation, it is hard to estimate the exact antimicrobial resistance (AMR) scenario. Also, it becomes difficult to compare the current situation with other countries in the region. Moreover, limited evidence exists on the trends of use of antimicrobial agents (AMA) in Maldives. Although, recent prescription audits have indicated overuse of antibiotics, especially for common conditions such as flu, cough and fever.
more
4th Meeting of NDPHS Expert Group on HIV, TB and AI Oslo, 1-2 March, 2017
Ce plan stratégique 2013- 2017 s’inscrit dans la continuité du précédent et a pour but de contribuer à la réduction de la charge de la tuberculose au Sénégal d’ici 2015 conformément aux Objectifs du Millénaire (OMD 6 Cible 8) et aux ci...bles du partenariat Halte à la tuberculose.
Les interventions porteront, principalement, sur les orientations stratégiques déclinées lors de la revue externe. Elles seront axées sur la poursuite d’une stratégie DOTS de qualité, le renforcement des interventions communautaires et la prise en charge des grands défi s (TB/VIH, TBMR, TB de l’enfant et le contrôle de l’infection). Durant cette période, l’implication des prestataires du privé sera accentuée et des stratégies de communication porteuses d’impact seront menées.
L’atteinte des objectifs de ce plan stratégique nécessitera une importante mobilisation de ressources et un plaidoyer fort sera mené auprès de tous les partenaires du secteur santé et en dehors.
more
NSP Review
Engaging with South Africa’s National Strategic Plan for HIV, STIs and TB Edition 7 July – August 2013
A publication of the Treatment Act...ion Campaign and SECTION27
GeneXpert: An imperfect rollout
TB in South African prisons: Where to now?
Decentralising DR-TB care: How far along are we?
more
54th directing council; 67th session of the regional Committee of WHO for the Americas
CD54/11, Rev. 1, 2 October 2015, Original: Spanish
Towards ending tuberculosis and multidrug-resistant tuberculosis.
The World Health Organization and the Global Fund to Fight AIDS, Tuberculosis and Malaria are part of a group of agencies working together to accelerate progress towards the health-related SDGs through the Global Action ...hlight medbox">Plan for Healthy Lives and Well-being for All. Understanding patterns of inequalities in these diseases is essential for taking strategic, evidence-informed action to realize our shared vision of ending the epidemics of HIV, TB and malaria.
This report presents the first comprehensive analysis of the magnitude and patterns of socioeconomic, demographic and geographic inequalities in disease burden and access to services for prevention and treatment.
The results confirm there have been improvements in service coverage and decreased disease burden at the national level over the past decade. But they also reveal an uncomfortable reality: unfair inequalities between population subgroups within countries are widespread and have remained largely unchanged over the past decade. For some disease indicators, inequalities are even worsening.
Moreover, the report points to the persistent lack of available data to fully understand inequality patterns in HIV, TB and malaria. Collecting data to improve the monitoring of inequalities in these diseases is vital to develop targeted responses for impact.
There are, encouragingly, isolated successes in reducing inequities. Change is possible when deliberate action is taken to reach disadvantaged populations.
more